The Human Genome Project (HGP) has bolstered the development of new technologies that utilize the projects comprehensive construction of genetic maps, physical maps, and DNA sequence data. Scientists apply this information, combined with bioinformatics and high throughput screening methods, to identify and develop novel drug candidates. One of the first drugs to come from the HGP and be used in clinical trials, Repifermin, was identified by a genomics company called Human Genome Sciences (HGSI) of Rockville, MD. HGSI uses sequencing data to identify genes like Repifermin. Repifermin, or keratinocyte Growth Factor-2 (KGF-2), is a human protein believed to be activated in response to epithelial wound damage. Its function is to attract cells involved in wound healing such as fibroblasts, collagen and connective tissue to site of the wound for tissue repair and regrowth. It was discovered while screening 10,000 different genes. HGSI found more than 300 full-length genes corresponding to...